학술논문
Energy metabolism during exercise in patients with β‐enolase deficiency (GSDXIII)
Document Type
Report
Author
Source
JIMD Reports. September 2021, Vol. 61 Issue 1, p60, 7 p.
Subject
Language
English
Abstract
Synopsis Patients with GSDXIII suffer from a mild glycolytic defect that limits maximal oxidative capacity. INTRODUCTION Enolase is the enzyme responsible for the penultimate step in glycolysis as it catalyzes [...]
: Aim: To investigate the in vivo skeletal muscle metabolism in patients with β‐enolase deficiency (GSDXIII) during exercise, and the effect of glucose infusion. Methods: Three patients with GSDXIII and 10 healthy controls performed a nonischemic handgrip test as well as an incremental cycle ergometer test measuring maximal oxidative consumption (VO[sub.2max]) and a 1‐hour submaximal cycle test at an intensity of 65% to 75% of VO[sub.2max]. The patients repeated the submaximal exercise after 2 days, where they received a 10% iv‐glucose supplementation. Results: Patients had lower VO[sub.2max] than healthy controls, and two of three patients had to stop prematurely during the intended 1‐hour submaximal exercise test. During nonischemic forearm test, all patients were able to produce lactate in normal amounts. Glucose infusion had no effect on patients' exercise capacity. Conclusions: Patients with GSDXIII experience exercise intolerance and episodes of myoglobinuria, even to the point of needing renal dialysis, but still retain an almost normal anaerobic metabolic response to submaximal intensity exercise. In accordance with this, glucose supplementation did not improve exercise capacity. The findings show that GSDXIII, although causing episodic rhabdomyolysis, is one of the mildest metabolic myopathies affecting glycolysis.
: Aim: To investigate the in vivo skeletal muscle metabolism in patients with β‐enolase deficiency (GSDXIII) during exercise, and the effect of glucose infusion. Methods: Three patients with GSDXIII and 10 healthy controls performed a nonischemic handgrip test as well as an incremental cycle ergometer test measuring maximal oxidative consumption (VO[sub.2max]) and a 1‐hour submaximal cycle test at an intensity of 65% to 75% of VO[sub.2max]. The patients repeated the submaximal exercise after 2 days, where they received a 10% iv‐glucose supplementation. Results: Patients had lower VO[sub.2max] than healthy controls, and two of three patients had to stop prematurely during the intended 1‐hour submaximal exercise test. During nonischemic forearm test, all patients were able to produce lactate in normal amounts. Glucose infusion had no effect on patients' exercise capacity. Conclusions: Patients with GSDXIII experience exercise intolerance and episodes of myoglobinuria, even to the point of needing renal dialysis, but still retain an almost normal anaerobic metabolic response to submaximal intensity exercise. In accordance with this, glucose supplementation did not improve exercise capacity. The findings show that GSDXIII, although causing episodic rhabdomyolysis, is one of the mildest metabolic myopathies affecting glycolysis.